Talazoparib,Enzalutamide,Olaparib,abiraterone,Niraparib,Prednisone
Pfizer,Astellas,Merck,AstraZeneca,Janssen
[]
excellent summary current state of parpi combination with asis.heterogeneity pointing to need for further refinement of target population. ratio risk / benefit critical #ascogu23 
Genitourinary Oncology Section Chief Houston Methodist Cancer Center